中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 11
Nov.  2018
Turn off MathJax
Article Contents

Research advances in gut microbiota in liver cirrhosis and related complications

DOI: 10.3969/j.issn.1001-5256.2018.11.037
Research funding:

 

  • Published Date: 2018-11-20
  • Liver cirrhosis is an end-stage fibrotic disease of chronic liver injury induced by various factors. Many studies have shown that gut microbiota ( GM) are involved in the development and progression of liver cirrhosis and related complications, such as portal hypertension, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatocellular carcinoma. In addition, impaired intestinal barrier, compromised liver immunity, and bacterial translocation play a critical role in the progression of liver cirrhosis. This article summarizes the role of GM in liver cirrhosis and related complications and research advances and problems in GM as a therapeutic target, in order to provide new thoughts for clinical diagnosis and treatment.

     

  • loading
  • [1]FUKUI H, SAITO H, UENO Y, et al.Evidence-based clinical practice guidelines for liver cirrhosis 2015[J].J Gastroenterol, 2016, 51 (7) :629-650.
    [2]QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature, 2010, 464 (7285) :59-65.
    [3]MIURA K, OHNISHI H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (23) :7381-7391.
    [4]WIEST R, ALBILLOS A, TRAUNER M, et al.Targeting the gutliver axis in liver disease[J].J Hepatol, 2017, 67 (5) :1084-1103.
    [5]TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.
    [6]SCHNABL B, BRENNER DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014, 146 (6) :1513-1524.
    [7]BAJAJ JS, BETRAPALLY NS, GILLEVET PM.Decompensated cirrhosis and microbiome interpretation[J].Nature, 2015, 525 (7569) :e1-e2.
    [8]BAJAJ JS, HEUMAN DM, HYLEMON PB, et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol, 2014, 60 (5) :940-947.
    [9]GARCIA-PAGAN JC, GRACIA-SANCHO J, BOSCH J.Functional aspects on the pathophysiology of portal hypertension in cirrhosis[J].JHepatol, 2012, 57 (2) :458-461.
    [10]MOGHADAMRAD S, MCCOY KD, GEUKING MB, et al.Attenuated portal hypertension in germ-free mice:Function of bacterial flora on the development of mesenteric lymphatic and blood vessels[J].Hepatology, 2015, 61 (5) :1685-1695.
    [11]QIN N, YANG F, LI A, et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature, 2014, 513 (7516) :59-64.
    [12]QUEVRAIN E, MAUBERT MA, MICHON C, et al.Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease[J].Gut, 2016, 65 (3) :415-425.
    [13]KANG DJ, BETRAPALLY NS, GHOSH SA, et al.Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice[J].Hepatology, 2016, 64 (4) :1232-1248.
    [14]AHLUWALIA V, BETRAPALLY NS, HYLEMON PB, et al.Impaired gut-liver-brain axis in patients with cirrhosis[J].Sci Rep, 2016, 6:26800.
    [15]BAJAJ JS, BETRAPALLY NS, HYLEMON PB, et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology, 2015, 62 (4) :1260-1271.
    [16]RIGGIO O, MANNAIONI G, RIDOLA L, et al.Peripheral and splanchnic indole and oxindole levels in cirrhotic patients:A study on the pathophysiology of hepatic encephalopathy[J].Am J Gastroenterol, 2010, 105 (6) :1374-1381.
    [17]MONTAGNESE S, BIANCARDI A, SCHIFF S, et al.Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis[J].Hepatology, 2011, 53 (2) :558-566.
    [18]HUANG R, NI JJ, GAO Y.The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.
    [19]LOO TM, KAMACHI F, WATANABE Y, et al.Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J].Cancer Discov, 2017, 7 (5) :522-538.
    [20]ZHOU LX, HAN T, LIU BW, et al.A preliminary analysis of composition and structure of intestinal microbiota in patients with liver cirrhosis or hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (9) :1740-1744. (in Chinese) 周冷潇, 韩涛, 刘保文, 等.肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析[J].临床肝胆病杂志, 2017, 33 (9) :1740-1744.
    [21]HACKSTEIN CP, ASSMUS LM, WELZ M, et al.Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis[J].Gut, 2017, 66 (3) :507-518.
    [22]CARNEVALE R, RAPARELLI V, NOCELLA C, et al.Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].J Hepatol, 2017, 67 (5) :950-956.
    [23]MUNOZ L, JOSE BORRERO M, UBEDA M, et al.Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis[J].Hepatology, 2012, 56 (5) :1861-1869.
    [24]STEIB CJ, HARTMANN AC, V HESLER C, et al.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis[J].Lab Invest, 2010, 90 (7) :1024-1032.
    [25]DOI H, IYER TK, CARPENTER E, et al.Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population[J].Hepatology, 2012, 55 (3) :709-719.
    [26]LEVY M, THAISS CA, ZEEVI D, et al.Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NL-RP6 inflammasome signaling[J].Cell, 2015, 163 (6) :1428-1443.
    [27]WIEST R, LAWSON M, GEUKING M.Pathological bacterial translocation in liver cirrhosis[J].J Hepatol, 2014, 60 (1) :197-209.
    [28]BELLOT P, GARCIA-PAGAN JC, FRANCES R, et al.Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis[J].Hepatology, 2010, 52 (6) :2044-2052.
    [29]TELTSCHIK Z, WIEST R, BEISNER J, et al.Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J].Hepatology, 2012, 55 (4) :1154-1163.
    [30]RYAN KK, TREMAROLI V, CLEMMENSEN C, et al.FXR is a molecular target for the effects of vertical sleeve gastrectomy[J].Nature, 2014, 509 (7499) :183-188.
    [31]JIANG C, XIE C, LI F, et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J].J Clin Invest, 2015, 125 (1) :386-402.
    [32]ARAB JP, KARPEN SJ, DAWSON PA, et al.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J].Hepatology, 2017, 65 (1) :350-362.
    [33]PARSEUS A, SOMMER N, SOMMER F, et al.Microbiota-induced obesity requires farnesoid X receptor[J].Gut, 2017, 66 (3) :429-437.
    [34]RIDLON JM, ALVES JM, HYLEMON PB, et al.Cirrhosis, bile acids and gut microbiota:Unraveling a complex relationship[J].Gut Microbes, 2013, 4 (5) :382-387.
    [35]KALAMBOKIS GN, MOUZAKI A, RODI M, et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :815-818.
    [36]ZHU Q, ZOU L, JAGAVELU K, et al.Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice[J].JHepatol, 2012, 56 (4) :893-899.
    [37]KANG SH, LEE YB, LEE JH, et al.Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J].Aliment Pharmacol Ther, 2017, 46 (9) :845-855.
    [38]LIANG S, WEBB T, LI Z.Probiotic antigens stimulate hepatic natural killer T cells[J].Immunology, 2014, 141 (2) :203-210.
    [39]LUNIA MK, SHARMA BC, SHARMA P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:A randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.e1.
    [40]BAJAJ JS, GILLEVET PM, PATEL NR, et al.A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy[J].Metab Brain Dis, 2012, 27 (2) :205-215.
    [41]TAUXE WM, HAYDEK JP, REBOLLEDO PA, et al.Fecal microbiota transplant for Clostridium difficile infection in older adults[J].Therap Adv Gastroenterol, 2016, 9 (3) :273-281.
    [42]GARCIA-LEZANA T, RAURELL I, BRAVO M, et al.Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J].Hepatology, 2018, 67 (4) :1485-1498.
    [43]VERBEKE L, FARRE R, TREBICKA J, et al.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats[J].Hepatology, 2014, 59 (6) :2286-2298.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1582) PDF downloads(444) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return